Imperial College Develops Prostate-Targeted mRNA Nanogels, Overcoming Liver Accumulation in Cancer Therapy

Imperial College London UK

Overview

Researchers at Imperial College London have developed prostate-targeted degradable polymer nanogels for mRNA delivery in prostate cancer treatment. This innovation overcomes the challenge of tissue-specific mRNA delivery, where conventional lipid nanoparticles tend to accumulate in the liver. The nanogels are designed to protect mRNA cargo in circulation, degrade within cancer cells to release mRNA, and suppress tumor growth, paving the way for more effective and safer gene therapy approaches for prostate cancer.

In Depth

Key Findings: Imperial College Develops Prostate-Targeted mRNA Nanogels to Solve Liver Accumulation Issue

A research team at Imperial College London has developed innovative prostate-targeted degradable polymer nanogels as an mRNA delivery system specifically for prostate cancer treatment. This breakthrough overcomes the long-standing challenge of liver accumulation commonly observed with conventional lipid nanoparticle (LNP)-based mRNA delivery, enabling selective mRNA delivery to specific tissues. This new nanogel system is expected to facilitate targeted gene therapy for tumors, contributing to improved therapeutic efficacy and reduced side effects.

Technical and Clinical Details: Precise mRNA Release Through Circulatory Protection and Intratumoral Degradation

The newly developed prostate-targeted degradable polymer nanogels are based on the following key functions and design principles:

• Protection of mRNA in Circulation: mRNA is unstable in vivo and easily degraded, so the nanogels play a crucial role in protecting the mRNA cargo during circulation. This ensures the stability of mRNA until it reaches the target tissue.
• Prostate Cancer-Specific Targeting: The surface of the nanogels is modified with ligands that specifically bind to receptors expressed on prostate cancer cells. This enables the nanogels to selectively accumulate in prostate cancer tissue via systemic circulation.
• Intratumoral Degradation and mRNA Release: The nanogels are designed to degrade under specific conditions within cancer cells or in the tumor microenvironment (e.g., low pH or presence of specific enzymes). This degradation effectively releases mRNA, which is then translated within cancer cells to express the desired protein, exerting its effect of suppressing tumor growth.

Traditional LNPs, due to their physicochemical properties, tend to accumulate predominantly in the liver when administered systemically, making it difficult to deliver mRNA to specific tissues other than the liver. This nanogel technology addresses this challenge by meticulously designing polymer materials and surface modifications to achieve high selectivity for the prostate. This precise targeting and controlled release hold the potential to significantly improve the safety and efficacy of mRNA therapeutics.

Background and Industry Context: New Hope for Prostate Cancer Treatment and Evolution of DDS

Prostate cancer is one of the most common cancers in men, and treatment options can be limited in advanced cases. Existing treatments include surgery, radiation therapy, hormone therapy, and chemotherapy, but these often come with side effects and issues of treatment resistance. mRNA-based gene therapy is expected to offer a new, more effective therapeutic approach for prostate cancer by targeting specific tumor-related genes or activating immune responses. However, efficient and safe mRNA delivery to target tissues has been a major challenge. This research from Imperial College symbolizes an innovation in drug delivery systems (DDS) to solve this challenge, bringing new hope to prostate cancer patients. It represents a significant step towards realizing more precise cancer treatments.

Future Outlook: Clinical Applications and Expansion to Diverse Diseases

The development of these prostate-targeted mRNA nanogels expands the potential for mRNA-based gene therapy to be applied to cancers in organs other than the liver. Future prospects include further evaluation of efficacy and safety in preclinical stages, and ultimately, progression to clinical trials. This nanogel technology may have broad applicability, not only for prostate cancer but also for developing mRNA therapeutics targeting other specific solid tumors or specific organs outside the liver. If this technology is commercialized, it is expected to lead to more effective cancer treatments with fewer side effects, significantly improving patient prognosis and quality of life.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime